Marinus Pharmaceuticals (NASDAQ:MRNS) Lifted to Hold at StockNews.com

StockNews.com upgraded shares of Marinus Pharmaceuticals (NASDAQ:MRNS) from a sell rating to a hold rating in a research note released on Monday.

Several other equities analysts also recently weighed in on MRNS. LADENBURG THALM/SH SH downgraded Marinus Pharmaceuticals from a buy rating to a neutral rating in a report on Wednesday, August 14th. HC Wainwright reissued a buy rating and issued a $11.00 target price on shares of Marinus Pharmaceuticals in a report on Wednesday, August 14th. Truist Financial reaffirmed a buy rating and set a $10.00 price objective on shares of Marinus Pharmaceuticals in a research report on Tuesday, June 18th. Finally, Cantor Fitzgerald reaffirmed an overweight rating and set a $13.00 target price on shares of Marinus Pharmaceuticals in a report on Monday. Five equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, Marinus Pharmaceuticals currently has a consensus rating of Hold and an average price target of $10.25.

Marinus Pharmaceuticals Price Performance

MRNS opened at $1.39 on Monday. The company has a current ratio of 2.28, a quick ratio of 2.15 and a debt-to-equity ratio of 5.68. The company has a market cap of $76.36 million, a price-to-earnings ratio of -0.53 and a beta of 1.13. The stock has a fifty day simple moving average of $1.34 and a two-hundred day simple moving average of $3.21. Marinus Pharmaceuticals has a 12-month low of $1.05 and a 12-month high of $11.26.

Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.01). Marinus Pharmaceuticals had a negative return on equity of 7,831.35% and a negative net margin of 493.14%. The business had revenue of $8.06 million for the quarter, compared to the consensus estimate of $9.05 million. During the same period in the previous year, the firm earned ($0.61) EPS. Research analysts predict that Marinus Pharmaceuticals will post -1.88 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in MRNS. AQR Capital Management LLC increased its holdings in shares of Marinus Pharmaceuticals by 70.3% in the second quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 12,934 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in Marinus Pharmaceuticals during the 2nd quarter valued at approximately $64,000. Squarepoint Ops LLC bought a new stake in Marinus Pharmaceuticals in the 2nd quarter worth approximately $206,000. Point72 DIFC Ltd bought a new stake in Marinus Pharmaceuticals in the 2nd quarter worth approximately $28,000. Finally, XTX Topco Ltd purchased a new stake in shares of Marinus Pharmaceuticals during the 2nd quarter worth approximately $232,000. Institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.